Scientific Advisory Board
Introducing the CHF Scientific Advisory Board
We’re excited to announce our Scientific Advisory Board! We are fortunate to be advised by world experts in NALCN and related diseases—spanning neurobiology, neurophysiology, translational science, pharmacology, gene therapies, and clinical research and care —who share our vision of a world free from NALCN diseases.
Learn more about our Scientific Advisory Board members.
New scientific publications
Two recent articles have highlighted the role of NALCN in other neurologic diseases:
- In a Parkinson's disease mouse model, downregulation of NALCN was found to contribute to pathological bursting activity in the pacemaking activity of neurons in the substantia nigra pars compacta of the basal ganglia. This suggests a role of decreased NALCN in Parkinson's disease, and the possibility that modulating NALCN could be treatment target for motor symptoms of Parkinson's disease.
- In a study evaluating the biology of chronic pain, NALCN was found to contribute to the resting membrane potential and firing of neurons involved in chronic pain pathways.
Publications on NALCN Channel-related disorders can be found here:
CHF
Worldwide Sodium Channel Conference
The Worldwide Sodium Channel Conference will be held January 31st to February 2nd, 2024 in Grindelwald, Switzerland. This seminar aims to bring together sodium channel researchers worldwide to share their latest findings, engage in discussions, and further our understanding of this fascinating protein family of the human body.
Kickoff of Quarterly CHF Webinar Series
This month, we kicked off the Quarterly CHF webinar series. We will hold webinars to distribute updates and connect with patient families, donors, subscribers, and followers. You can access the link to the recording for our first webinar here.
Our next Webinar will be held in January 2024.
